Lupin's Goa plant is under US drug regulator's scanner Lupin shares sank over 8 per cent on Friday, even though analysts described the drugmaker's Q4 results as positive. Lupin, India's third-largest drugmaker, reported a higher than expected ... NDTV Profit, 1 week ago
Goa plant woes a key overhang on Lupin: Experts - Moneycontrol.com, 1 week ago
Dr Reddy's Pathlabs reported a sharp decline in its net profit of FY16 at Rs 74.6 crore over Rs 518.9 crore a year ago, due to one-time write-offs of Rs 430.9 crore from its Venezuelan business. The company has mentioned in its earnings report that ...Moneycontrol.com, 2 weeks ago
The decision by Taro Pharma, Sun Pharma's Israeli subsidiary, to provide keveyis free of cost to distributors is likely to impact revenues of about USD 25 million, says Praful Bohra, VP Research at Religare.Money Control, 3 weeks ago
The government over the weekend banned 344 Fixed Dose Combinations (FDCs) drugs, which will impact nearly 4-5 percent of the Indian pharmaceutical industry. Kewal Handa, industry expert and former MD of Pfizer says that alongwith sales loss, ...Moneycontrol.com, 2 months ago
on your WebpageAdd Widget >Get your members hooked!